Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Kakolyris S, Ziras N, Vamvakas L, Varthalitis J, Papakotoulas P, Syrigos K, Vardakis N, Kalykaki A, Amarantidis K, Georgoulias V. Kakolyris S, et al. Among authors: amarantidis k. Lung Cancer. 2006 Dec;54(3):347-52. doi: 10.1016/j.lungcan.2006.09.001. Epub 2006 Oct 9. Lung Cancer. 2006. PMID: 17030075 Clinical Trial.
Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.
Kakolyris S, Kalbakis K, Potamianou A, Malamos N, Vamvakas L, Christophillakis C, Tselepatiotis E, Giassas S, Mavroudis D, Amarantidis K, Georgoulias V. Kakolyris S, et al. Among authors: amarantidis k. Oncology. 2006;70(4):273-9. doi: 10.1159/000096248. Epub 2006 Oct 12. Oncology. 2006. PMID: 17047398 Clinical Trial.
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V; Hellenic Oncology Research Group. Kakolyris S, et al. Among authors: amarantidis k. Oncology. 2008;74(1-2):31-6. doi: 10.1159/000138977. Epub 2008 Jun 10. Oncology. 2008. PMID: 18544957 Clinical Trial.
Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
Xenidis N, Neanidis K, Amarantidis K, Dimopoulos P, Chamalidou E, Pitsiava D, Tentes A, Chatzaki E, Karakitsos P, Kakolyris S. Xenidis N, et al. Among authors: amarantidis k. Cancer Chemother Pharmacol. 2011 Jan;67(1):69-73. doi: 10.1007/s00280-010-1284-2. Epub 2010 Mar 11. Cancer Chemother Pharmacol. 2011. PMID: 20221602 Clinical Trial.
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Xenidis N, Chelis L, Amarantidis K, Chamalidou E, Dimopoulos P, Courcoutsakis N, Tentes A, Chiotis A, Prassopoulos P, Kakolyris S. Xenidis N, et al. Among authors: amarantidis k. Cancer Chemother Pharmacol. 2012 Feb;69(2):477-84. doi: 10.1007/s00280-011-1717-6. Epub 2011 Aug 20. Cancer Chemother Pharmacol. 2012. PMID: 21858532 Clinical Trial.
30 results